Ivermectin and Human Immunity

• Status: Completed
• Trial end date: 2018-11-30
• Target enrollment: 0
• Participant gender: All

Summary

We hypothesize that ivermectin, a drug used to treat parasitic worm infections, interacts with the human innate immune system and that this contributes to its anti-parasitic effects. Participants will donate blood before and after being administered the normal human dose of the drug. We will compare the cell types present in the blood and the chemicals known to influence the human immune system before and after the drug is given, as well as measuring any changes in gene expression in white blood cells 4 and 24hrs after the drug is taken.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Georgia
• Treatments: Ivermectin

Criteria

Inclusion Criteria:

• Weight over 110 pounds and under 185 pounds

Exclusion Criteria:

• Pregnancy or nursing mothers.

• Immunosuppressed individuals.

• Hypersensitivity to ivermectin, cellulose, starch, magnesium stearate, butylated hydroxyanisole, or citric acid powder (inert ingredients of Stromectol).

• Recent (last 3 years) travel to West or Central Africa, or any other country where onchocerciasis is present

• Hepatitis/HIV

• Currently taking warfarin

• Lactose intolerance (Lactose present in placebo)

• Currently taking Steroid medications (inhaled, oral or injection)

• Currently taking Barbiturates, Benzodiazepines such as Xanax or Klonopin, Valproic acid (Lithium), Calcium channel blockers, Statins (cholesterol medication)

• Liver or renal dysfunction